Categories: Health

LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025

BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.

Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at ir.lemaitre.com.

About LeMaitre

LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.

LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.



GlobeNews Wire

Recent Posts

NOTICE TO DISREGARD — Sophos Inc.

March 03, 2026 11:03 ET  | Source: Sophos Inc. OXFORD, United Kingdom and CARMEL, Indiana,…

2 hours ago

Orangekloud Technology Inc. Regains Compliance with Nasdaq Listing Requirements

Singapore, March 03, 2026 (GLOBE NEWSWIRE) -- Orangekloud Technology Inc. (NASDAQ: ORKT) (“Orangekloud” or the…

2 hours ago

TestMu AI Adds Samsung Galaxy S26 Series to Virtual and Real Device Cloud Ahead of Public Release

Developers and QA teams can validate apps on Samsung’s latest flagship devices weeks before they…

2 hours ago

Persevere Therapeutics Launches as a Clinical-Stage Oncology Company with a Novel Phase 1b/2a Agent and Announces First Close of Seed Financing

Chesterbrook, PA, March 03, 2026 (GLOBE NEWSWIRE) -- Persevere Therapeutics, Inc. (“Persevere”), a Delaware-incorporated, clinical-stage…

3 hours ago

Inteleos 2026 Leadership Elections Accelerate Vision for Global Healthcare

ROCKVILLE, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Inteleos today announced its 2026 leadership elections…

3 hours ago

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed”…

3 hours ago